Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017112536) CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/112536 International Application No.: PCT/US2016/067120
Publication Date: 29.06.2017 International Filing Date: 16.12.2016
IPC:
A61K 39/395 (2006.01) ,A61K 39/00 (2006.01) ,G01N 33/53 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
Applicants:
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, California 91320-1799, US
MEDIMMUNE, LLC [US/US]; One Medimmune Way Gaithersburg, Maryland 20878, US
Inventors:
GEORGANTAS, Robert W. III; US
MOREHOUSE, Chris; US
HIGGS, Brandon; US
RANADE, Koustubh; US
STREICHER, Katie; US
REES, William; US
LIANG, Meina; US
FAGGIONI, Raffaella; US
LI, Jing; US
VAINSHTEIN, Inna; US
LEE, Yen-Wah; US
CHEN, Jingjing; US
GASSER, Robert A., Jr.; US
Agent:
NOLAND, Greta E.; US
Priority Data:
62/271,15622.12.2015US
Title (EN) CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS
(FR) CCL20 EN TANT QUE PRÉDICTEUR DE RÉPONSE CLINIQUE AUX ANTAGONISTES D’IL23
Abstract:
(EN) The present invention relates to the use of the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
(FR) La présente invention concerne l'utilisation du ligand 20 (CCL20) Chimiokine (motif C-C) en tant que biomarqueur pour stratifier ou identifier des populations de patients atteints de maladies (par exemple, la maladie de Crohn) médiées par l’interleukine 23 (IL23), sensibles à un traitement avec un antagoniste anti-IL23 (dont, par exemple, les anticorps anti-IL23). Des niveaux de CCL20 supérieurs ou inférieurs à un seuil prédéterminé peuvent être utilisés, par exemple, (i) pour déterminer si un patient atteint d'une maladie ou d’un trouble médié par IL23 tel que la maladie de Crohn est éligible ou non éligible à un traitement avec un agent thérapeutique, (ii) pour déterminer si le traitement avec un certain agent doit être ou non commencé, suspendu ou modifié, (iii) pour diagnostiquer si la maladie médiée par IL23 peut être traitée ou non avec un agent thérapeutique spécifique, ou (iv) pour prédire le résultat du traitement de la maladie médiée par IL23 avec un agent thérapeutique spécifique. CCL20 peut être utilisé combiné à d'autres biomarqueurs de la voie IL23 tels qu’IL22 et/ou la lipocaline 2 (LCN2).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2016379157CA3007098MYPI 2018000913IL259704CN108472367KR1020180096633
EP3393515BR112018012626